More about

Pegozafermin

News
November 27, 2023
2 min read
Save

ENLIVEN extension topline data: Pegozafermin sustains ‘robust benefits’ in NASH at week 48

Topline findings from an extension of the phase 2b ENLIVEN trial showed that pegozafermin sustained improvements in fibrosis and disease resolution for patients with nonalcoholic steatohepatitis at 48 weeks, 89bio announced.